Investor Overview
Vaccinex, Inc. is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. The company’s lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntington’s, Alzheimer’s and other neurodegenerative diseases.
Beyond neurology, Vaccinex has determined that, in combination with checkpoint inhibitors, pepinemab has potential to increase objective responses in oncology. The company additionally intends to leverage its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations.
Corporate Governance
The Board of Directors of Vaccinex (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.
Investor Services
Primary IR Contact
Elizabeth Evans, Ph.D.
Chief Operating Officer
Vaccinex, Inc
Phone: (585) 271-2700
E-mail: eevans@vaccinex.com
Shareholder Contact
Investor Centre Website
www.computershare.com/investor
Telephone inquiries
877-373-6374 (US, Canada, Puerto Rico)
781-575-3100 (non-US)
Written requests
Computershare
P.O. Box 43006
Providence, RI 02940-3078
By overnight delivery:
Computershare
150 Royall St., Suite 101
Canton, MA 02021
web.queries@computershare.com
Shareholder Online Inquiries
https://www-us.computershare.com/investor/Contact